Real-world effectiveness of COVID-19 vaccination in liver cirrhosis: a systematic review with meta-analysis of 51,834 patients
dc.contributor.author | Beran, Azizullah | |
dc.contributor.author | Mhanna, Asmaa | |
dc.contributor.author | Mhanna, Mohammed | |
dc.contributor.author | Hassouneh, Ramzi | |
dc.contributor.author | Abuhelwa, Ziad | |
dc.contributor.author | Mohamed, Mouhand F. H. | |
dc.contributor.author | Sayeh, Wasef | |
dc.contributor.author | Musallam, Rami | |
dc.contributor.author | Assaly, Ragheb | |
dc.contributor.author | Abdeljawad, Khaled | |
dc.contributor.department | Medicine, School of Medicine | |
dc.date.accessioned | 2023-11-02T12:43:35Z | |
dc.date.available | 2023-11-02T12:43:35Z | |
dc.date.issued | 2023-01-17 | |
dc.description.abstract | SARS-CoV-2 vaccinations were found to be highly effective in phase 3 clinical trials. However, these trials have not reported data regarding the subgroup of liver disease or excluded patients with liver disease. The effectiveness of COVID-19 vaccines among liver cirrhosis (LC) patients is unclear. We conducted this meta-analysis to assess the effectiveness of SARS-CoV-2 vaccination in LC patients. A comprehensive literature search was conducted to include all the relevant studies that compared the outcomes of LC patients who received SARS-CoV-2 vaccines vs. unvaccinated patients. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated by the Mantel-Haenszel method within a random-effect model. Four studies with 51,834 LC patients (20,689 patients received at least one dose vs 31,145 were unvaccinated) were included. COVID-19–related complications, including hospitalization (RR 0.73, 95% CI 0.59–0.91, P = 0.004), mortality (RR 0.29, 95% CI 0.16–0.55, P = 0.0001), and need for invasive mechanical ventilation (RR 0.29, 95% CI 0.11–0.77, P = 0.01), were significantly lower in the vaccinated group compared to the unvaccinated group. SARS-CoV-2 vaccination in LC patients reduced COVID-19–related mortality, intubation, and hospitalization. SARS-CoV-2 vaccination is highly effective in LC. Further prospective studies, preferably randomized controlled trials, are necessary to validate our findings and determine which vaccine is superior in patients with LC. | |
dc.eprint.version | Final published version | |
dc.identifier.citation | Beran A, Mhanna A, Mhanna M, et al. Real-world effectiveness of COVID-19 vaccination in liver cirrhosis: a systematic review with meta-analysis of 51,834 patients. Proc (Bayl Univ Med Cent). 2023;36(2):151-156. Published 2023 Jan 17. doi:10.1080/08998280.2023.2165344 | |
dc.identifier.uri | https://hdl.handle.net/1805/36893 | |
dc.language.iso | en_US | |
dc.publisher | Taylor & Francis | |
dc.relation.isversionof | 10.1080/08998280.2023.2165344 | |
dc.relation.journal | Baylor University Medical Center Proceedings | |
dc.rights | Publisher Policy | |
dc.source | PMC | |
dc.subject | Chronic liver disease | |
dc.subject | COVID-19 vaccine | |
dc.subject | Liver cirrhosis | |
dc.subject | SARS-CoV-2 vaccine | |
dc.title | Real-world effectiveness of COVID-19 vaccination in liver cirrhosis: a systematic review with meta-analysis of 51,834 patients | |
dc.type | Article | |
ul.alternative.fulltext | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980592/ |